Evaluation of the clinical age-related maculopathy staging system.

[1]  Johanna M Seddon,et al.  The US twin study of age-related macular degeneration: relative roles of genetic and environmental influences. , 2005, Archives of ophthalmology.

[2]  P. Jong.  Prevalence of age-related macular degeneration in the United States. , 2004 .

[3]  B S Hawkins,et al.  Epidemiology of age-related macular degeneration. , 1999, Molecular vision.

[4]  B. Rosner,et al.  Progression of age-related macular degeneration: association with dietary fat, transunsaturated fat, nuts, and fish intake. , 2003, Archives of ophthalmology.

[5]  Johanna M Seddon,et al.  Potential public health impact of Age-Related Eye Disease Study results: AREDS report no. 11. , 2003, Archives of ophthalmology.

[6]  S. Santangelo,et al.  A genomewide scan for age-related macular degeneration provides evidence for linkage to several chromosomal regions. , 2003, American journal of human genetics.

[7]  A. Ho.  Progression of Age-Related Macular Degeneration , 2003 .

[8]  Matthew D. Davis,et al.  Proposed international clinical diabetic retinopathy and diabetic macular edema disease severity scales. , 2003, Ophthalmology.

[9]  Usha Chakravarthy,et al.  Grading of age-related maculopathy for epidemiological studies: is digital imaging as good as 35-mm film? , 2003, Ophthalmology.

[10]  B. Rosner,et al.  Progression of age-related macular degeneration: association with body mass index, waist circumference, and waist-hip ratio. , 2003, Archives of ophthalmology.

[11]  J. Lupski,et al.  Genotype-phenotype analysis of ABCR variants in macular degeneration probands and siblings. , 2002, Investigative ophthalmology & visual science.

[12]  A. Hutchinson,et al.  Assessment of mutations in the Best macular dystrophy (VMD2) gene in patients with adult-onset foveomacular vitelliform dystrophy, age-related maculopathy, and bull's-eye maculopathy. , 2001, Ophthalmology.

[13]  N. Bressler,et al.  Photodynamic therapy of subfoveal choroidal neovascularization in age-related macular degeneration with verteporfin: one-year results of 2 randomized clinical trials--TAP report. Treatment of age-related macular degeneration with photodynamic therapy (TAP) Study Group. , 1999, Archives of ophthalmology.

[14]  T. Stokkermans,et al.  Treatment of age-related macular degeneration. , 2000, Clinical eye and vision care.

[15]  A. Cruess,et al.  Interobserver agreement in the evaluation of acute retinal artery occlusion. , 1997, Canadian journal of ophthalmology. Journal canadien d'ophtalmologie.

[16]  J. Sparrow,et al.  The Wisconsin Age-related Macular Degeneration grading system: performance in an independent centre. , 1997, Ophthalmic epidemiology.

[17]  Paul S. Bernstein,et al.  Mutation of the Stargardt Disease Gene (ABCR) in Age-Related Macular Degeneration , 1997 .

[18]  J. Haines,et al.  Phenotypic heterogeneity in families with age-related macular degeneration. , 1996, American journal of ophthalmology.

[19]  R. Klein,et al.  The Wisconsin age-related maculopathy grading system. , 1991, Ophthalmology.

[20]  R D Sperduto,et al.  Evaluation of an iris color classification system. The Eye Disorders Case-Control Study Group. , 1990, Investigative ophthalmology & visual science.

[21]  J. R. Landis,et al.  The measurement of observer agreement for categorical data. , 1977, Biometrics.

[22]  Gary G. Koch,et al.  A review of statistical methods in the analysis of data arising from observer reliability studies (Part II) , 1975 .

[23]  John N. Hall,et al.  Inter-rater Reliability of Ward Rating Scales , 1974, British Journal of Psychiatry.

[24]  Jacob Cohen,et al.  Weighted kappa: Nominal scale agreement provision for scaled disagreement or partial credit. , 1968 .

[25]  C. Walker.  Ophthalmology , 1859, Bristol medico-chirurgical journal.

[26]  Robert J. Glynn,et al.  Evaluation of an Iris Color Classification System , 2005 .

[27]  Benita J. O’Colmain,et al.  Prevalence of age-related macular degeneration in the United States. , 2004, Archives of ophthalmology.

[28]  Ronald Klein,et al.  The epidemiology of age-related macular degeneration. , 2004, American journal of ophthalmology.

[29]  S. Harding.  Treatment of Age-Related Macular Degeneration with Photodynamic Therapy (TAP) Study Group. Verteporfin therapy for subfoveal choroidal neovascularization in age-related macular degeneration: three-year results of an open-label extension of 2 randomized clinical trials¿TAP Report No. 5 , 2002 .

[30]  The Age-Related Eye Disease Study system for classifying age-related macular degeneration from stereoscopic color fundus photographs: the Age-Related Eye Disease Study Report Number 6. , 2001, American journal of ophthalmology.

[31]  A Randomized, Placebo-Controlled, Clinical Trial of High-Dose Supplementation With Vitamins C and E, Beta Carotene, and Zinc for Age-Related Macular Degeneration and Vision Loss , 2001 .

[32]  Jennifer I. Lim,et al.  A randomized, placebo-controlled, clinical trial of high-dose supplementation with vitamins C and E, beta carotene, and zinc for age-related macular degeneration and vision loss: AREDS report no. 8. , 2001, Archives of ophthalmology.

[33]  N. Bressler.  Photodynamic therapy of subfoveal choroidal neovascularization in age-related macular degeneration with verteporfin: two-year results of 2 randomized clinical trials-tap report 2. , 2001 .

[34]  R. Klein,et al.  The five-year incidence and progression of age-related maculopathy: the Beaver Dam Eye Study. , 1997, Ophthalmology.

[35]  N. Bressler,et al.  Interobserver and intraobserver reliability in the clinical classification of drusen. , 1988, Retina.